Literature DB >> 9311844

Expression of gp19K increases the persistence of transgene expression from an adenovirus vector in the mouse lung and liver.

J T Bruder1, T Jie, D L McVey, I Kovesdi.   

Abstract

Activation of the cellular immune system and subsequent lysis of vector-transduced cells by adenovirus- or transgene-specific cytotoxic T lymphocytes have been shown to limit transgene expression in animal models. The adenovirus gp19K gene product associates with major histocompatibility complex class I proteins and prevents their maturation by sequestering them in the endoplasmic reticulum. gp19K has been shown to block the ability of adenovirus-specific cytotoxic T lymphocytes to recognize virus-infected cells in vitro. To determine if gp19K expression in an adenovirus vector would increase transgene persistence, a vector that replaces the E1 region of adenovirus with an expression cassette encoding both gp19K and beta-glucuronidase was constructed. This vector produced high levels of functional gp19K in infected cells. RNase protection analysis revealed efficient expression of the gp19K gene in the mouse lung. Enhanced persistence and increased beta-glucuronidase activity were observed in the lung and liver following delivery of the gp19K-expressing adenovirus vector in B10.HTG mice but not in BALB/c mice. Since gp19K binds to both class I alleles on B10.HTG mice but only one allele on BALB/c mice, these results suggest that the major histocompatibility complex class I haplotype of mice is important in determining the effectiveness of gp19K in vivo. Since gp19K has previously been shown to interact with every human major histocompatibility complex class I allele tested, the inclusion of gp19K in gene therapy vectors may increase vector persistence in human gene therapy trials.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9311844      PMCID: PMC192111          DOI: 10.1128/JVI.71.10.7623-7628.1997

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

1.  Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration.

Authors:  M A Kay; A X Holterman; L Meuse; A Gown; H D Ochs; P S Linsley; C B Wilson
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

2.  The constitutive expression of the immunomodulatory gp19k protein in E1-, E3- adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector.

Authors:  M G Lee; M A Abina; H Haddada; M Perricaudet
Journal:  Gene Ther       Date:  1995-06       Impact factor: 5.250

3.  Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy.

Authors:  Y Yang; F A Nunes; K Berencsi; E E Furth; E Gönczöl; J M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

4.  Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses.

Authors:  Y Yang; Q Li; H C Ertl; J M Wilson
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

5.  Association of human class I MHC alleles with the adenovirus E3/19K protein.

Authors:  D C Beier; J H Cox; D R Vining; P Cresswell; V H Engelhard
Journal:  J Immunol       Date:  1994-04-15       Impact factor: 5.422

6.  Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver.

Authors:  J F Engelhardt; X Ye; B Doranz; J M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

7.  Characterization of factors involved in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung.

Authors:  J M Kaplan; D Armentano; T E Sparer; S G Wynn; P A Peterson; S C Wadsworth; K K Couture; S E Pennington; J A St George; L R Gooding; A E Smith
Journal:  Hum Gene Ther       Date:  1997-01-01       Impact factor: 5.695

8.  Expression of adenovirus E3/19K protein does not alter mouse MHC class I-restricted responses to vaccinia virus.

Authors:  J H Cox; R M Buller; J R Bennink; J W Yewdell; G Karupiah
Journal:  Virology       Date:  1994-11-01       Impact factor: 3.616

9.  Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung.

Authors:  Y Yang; G Trinchieri; J M Wilson
Journal:  Nat Med       Date:  1995-09       Impact factor: 53.440

10.  MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses.

Authors:  Y Yang; H C Ertl; J M Wilson
Journal:  Immunity       Date:  1994-08       Impact factor: 31.745

View more
  9 in total

Review 1.  The promise and potential hazards of adenovirus gene therapy.

Authors:  L S Young; V Mautner
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

2.  Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen.

Authors:  T Kurihara; D E Brough; I Kovesdi; D W Kufe
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

3.  Ex vivo adenovirus mediated gene transfection of human conjunctival epithelium.

Authors:  J Shen; N Taylor; L Duncan; I Kovesdi; J T Bruder; J V Forrester; A D Dick
Journal:  Br J Ophthalmol       Date:  2001-07       Impact factor: 4.638

4.  A helper-independent adenovirus vector with E1, E3, and fiber deleted: structure and infectivity of fiberless particles.

Authors:  D J Von Seggern; C Y Chiu; S K Fleck; P L Stewart; G R Nemerow
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

Review 5.  Association of intracellular proteins with folded major histocompatibility complex class I molecules.

Authors:  Chantey R Morris; Adrian J Reber; Jason L Petersen; Shanna E Vargas; Joyce C Solheim
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

6.  Efficient, repeated adenovirus-mediated gene transfer in mice lacking both tumor necrosis factor alpha and lymphotoxin alpha.

Authors:  K Benihoud; I Saggio; P Opolon; B Salone; F Amiot; E Connault; C Chianale; F Dautry; P Yeh; M Perricaudet
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

Review 7.  Immunomodulatory functions encoded by the E3 transcription unit of adenoviruses.

Authors:  H G Burgert; J H Blusch
Journal:  Virus Genes       Date:  2000       Impact factor: 2.198

8.  Improving adenovirus based gene transfer: strategies to accomplish immune evasion.

Authors:  Sergey S Seregin; Andrea Amalfitano
Journal:  Viruses       Date:  2010-09-24       Impact factor: 5.818

9.  The human adenovirus type 5 E1B 55 kDa protein obstructs inhibition of viral replication by type I interferon in normal human cells.

Authors:  Jasdave S Chahal; Ji Qi; S J Flint
Journal:  PLoS Pathog       Date:  2012-08-09       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.